NuvaRing

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved October 2001

Specific Treatments:

Female contraception

Find Related Trials for The Following Conditions

General Information

NuvaRing is the first monthly vaginal ring approved for birth control. It is a flexible, transparent ring that provides month-long contraceptive protection through the continuous release of estrogen and progestin over a 21 day period of use.

NuvaRing conveniently fits into a woman's active lifestyle. It is simply inserted once a month, removing any daily worries over birth control. As exact positioning is not critical, NuvaRing cannot be inserted incorrectly.

As with use of other combination hormonal contraceptives, women using NuvaRing are strongly advised against smoking.

Clinical Results

Approval of NuvaRing is based on positive results from two larger clinical trials conducted worldwide with 2,322 women who were exposed to 23,289 cycles of NuvaRing. Pregnancy rates were between one and two percent.

Side Effects

Adverse events associated with the use of NuvaRing may include (but are not limited to) the following:


  • Vaginitis
  • Headache
  • Upper respiratory tract infection
  • Leukorrhea
  • Sinusitis
  • Weight gain
  • Nausea

Mechanism of Action

NuvaRing releases a continuous low dose of ethinyl estadiol, an estrogen, and etonogestrel, a progestin. Combination contraceptives work through the suppression of gonadotropins. Their primary function is the inhibition of ovulation; such contraceptives also alter the cervical mucus, which increases the difficulty of sperm entry to the uterus. Progesterone also makes the endometrium less favorable for implantation.

Additional Information

For additional information on Nuvaring, please visit Nuvaring.